MYC and breast cancer: Further investigation of ESR1 mutant in a clinical breast cancer cohort (SCAN-B31; n cases = 27; n controls = 108, see Methods for details) largely confirmed our cell model results (top enriched pathways: E2F targets, G2M checkpoint, MYC targets, and mTORC1 signaling; Fig. S8B).